RESEARCH ARTICLE
Infection reporting in patients undergoing irreversible electroporation of locally advanced pancreatic cancer
Anthony Filson MS,
Robert C. G. Martin MD, PhD,
Anthony Filson MS
Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, Kentucky, USA
Search for more papers by this authorCorresponding Author
Robert C. G. Martin MD, PhD
Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, Kentucky, USA
Correspondence Robert C. G. Martin, MD, PhD, Division of Surgical Oncology, University of Louisville School of Medicine, 315 E. Broadway M10, Louisville, KY 40202, USA.
Email: [email protected]
Search for more papers by this authorAnthony Filson MS,
Robert C. G. Martin MD, PhD,
Anthony Filson MS
Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, Kentucky, USA
Search for more papers by this authorCorresponding Author
Robert C. G. Martin MD, PhD
Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, Kentucky, USA
Correspondence Robert C. G. Martin, MD, PhD, Division of Surgical Oncology, University of Louisville School of Medicine, 315 E. Broadway M10, Louisville, KY 40202, USA.
Email: [email protected]
Search for more papers by this authorFirst published: 11 May 2023
Abstract
Background
Intraoperative bile cultures (IOBCs) taken during pancreatic surgery are commonly performed and there has been limited evidence that a positive IOBC could aid in perioperative adverse event (AE) management. Therefore, this study aims to describe infection management in patients undergoing irreversible electroporation (IRE).
Methods
An Institutional Review Board (IRB)-approved prospective database was utilized from 8/2016 to 6/2022, with 127 pancreatic adenocarcinoma patients included.
Results
A total of 28 patients that underwent IRE also had a simultaneous positive IOBC and the remaining 99 patients that underwent IRE had negative IOBC. A total of 11(39%) of the patients with a positive IOBC had AE's, and 38 (38%) of the patients with negative IOBC had AE's. Both groups had similar rates of AEs leading to new hospitalization and prolonged hospitalizations. Overall, there was no correlation between a positive IOBC and a patient developing an AE.
Conclusions
The findings of this study provide insights that improve the infectious management of patients undergoing IRE.
CONFLICT OF INTEREST STATEMENT
Dr. Robert Martin is a paid educational consultant for AngioDynamics.
Open Research
DATA AVAILABILITY STATEMENT
The data sets supporting the conclusions of this article are included within the article.
REFERENCES
- 1 Institute NC. SEER Cancer Statistics Review 1975-2013. https://seer.cancer.gov/archive/csr/1975_2013/results_merged/sect_22_pancreas.pdf. Accessed 5/22/2018, 2018.
- 2 Institute NC. SEER Stat Fact Sheets: Pancreas Cancer. http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed 5/18/2022, 2018.
- 3Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8): 1035-1046.
- 4Rossi ML. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol. 2014; 20(32): 11142-11159.
- 5Mohammed S, Van Buren 2nd G, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014; 20(28): 9354-9360.
- 6Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol. 2015; 21(11): 3157-3165.
- 7Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract. 2014; 2014: 1-9.
- 8Martin 2nd RC. Use of irreversible electroporation in unresectable pancreatic cancer. Hepatobiliary Surg Nutr. 2015; 4(3): 211-215.
- 9Bhutiani N, Davidyuk V, Mortensen GF, et al. Safety, efficacy, and technical details of endoscopic retrograde cholangiopancreatography after irreversible electroporation for locally advanced pancreatic cancer. J Gastrointest Surg. 2020; 24(5): 1077-1081.
- 10Martin 2nd RCG, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015; 262(3): 486-494 discussion 492-484.
- 11Martin RC, Philips P, Ellis S, Hayes D, Bagla S. Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation. BMC Cancer. 2014; 14: 540.
- 12Philips P, Hays D, Martin RCG. Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS One. 2013; 8(11):e76260.
- 13Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011; 104(1): 22-28.
- 14Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1): 11-20.
- 15Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018; 105(8): 946-958.
- 16Katz MHG, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016; 151(8):e161137.
- 17Mullen J, Lee J, Gomez H, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg. 2005; 9(8): 1094-1105 discussion 1104-1095.
- 18Gavazzi F, Ridolfi C, Capretti G, et al. Role of preoperative biliary stents, bile contamination and antibiotic prophylaxis in surgical site infections after pancreaticoduodenectomy. BMC Gastroenterol. 2016; 16: 43.
- 19Sewnath ME, Karsten TM, Prins MH, Rauws EJA, Obertop H, Gouma DJ. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 2002; 236(1): 17-27.
- 20Parapini ML, Skipworth JRA, Mah A, et al. The association between bacterobilia and the risk of postoperative complications following pancreaticoduodenectomy. HPB. 2022; 24(2): 277-285.
- 21Mohan A, Gupta R, Yadav TD, et al. Association of intra-operative bile culture with post-operative complications after pancreaticoduodenectomy. Surg Infect. 2022; 23(4): 351-356.
- 22Ohgi K, Sugiura T, Yamamoto Y, Okamura Y, Ito T, Uesaka K. Bacterobilia may trigger the development and severity of pancreatic fistula after pancreatoduodenectomy. Surgery. 2016; 160(3): 725-730.
- 23Lin YJ, Ho TW, Wu CH, et al. Specific bile microorganisms caused by intra-abdominal abscess on pancreaticoduodenectomy patients: a retrospective cohort study. Curr Oncol. 2021; 29(1): 111-121.
- 24Pretzsch E, Heim A, Heiliger C, et al. Specific intraoperative antibiotic therapy abrogates the negative effect of biliary contamination on the comprehensive complication index after pancreatic head resection. Surgery. 2021; 171(6): 1642-1651.
- 25Müssle B, Hempel S, Kahlert C, Distler M, Weitz J, Welsch T. Prognostic impact of bacterobilia on morbidity and postoperative management after pancreatoduodenectomy: a systematic review and meta-analysis. World J Surg. 2018; 42(9): 2951-2962.
- 26Mohammed S, Evans C, VanBuren G, et al. Treatment of bacteriobilia decreases wound infection rates after pancreaticoduodenectomy. HPB. 2014; 16(6): 592-598.
- 27Limongelli P, Pai M, Bansi D, et al. Correlation between preoperative biliary drainage, bile duct contamination, and postoperative outcomes for pancreatic surgery. Surgery. 2007; 142(3): 313-318.
- 28Kwon D, McFarland K, Velanovich V, Martin 2nd RCG. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery. 2014; 156(4): 910-922.
- 29Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250(2): 187-196.
- 30Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018; 379(25): 2395-2406.
- 31Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691-1703.
- 32White RR, Murphy JD, Martin RCG. The landmark series: locally advanced pancreatic cancer and ablative therapy options. Ann Surg Oncol. 2021; 28(8): 4173-4180.
- 33Martin RCG. Irreversible electroporation of locally advanced pancreatic head adenocarcinoma. J Gastrointest Surg. 2013; 17(10): 1850-1856.
- 34Dunki-Jacobs EM, Philips P, Martin 2nd RC. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg. 2014; 218(2): 179-187.
- 35Martin 2nd RC. Irreversible electroporation of locally advanced pancreatic neck/body adenocarcinoma. J Gastrointest Oncol. 2015; 6(3): 329-335.
- 36Holland MM, Bhutiani N, Kruse EJ, et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB. 2019; 21(8): 1024-1031.
- 37Martin 2nd RCG, Durham AN, Besselink MG, et al. Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery. J Surg Oncol. 2016; 114(7): 865-871.
- 38Cannon R, Ellis S, Hayes D, Narayanan G, Martin 2nd RCG. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013; 107(5): 544-549.
- 39Martin RC, Schwartz E, Adams J, Farah I, Derhake BM. Intra-operative anesthesia management in patients undergoing surgical irreversible electroporation of the pancreas, liver, kidney, and retroperitoneal tumors. Anesth Pain Med. 2015; 5(3):e22786.
- 40Bhutiani N, Doughtie CA, Martin 2nd RCG. Ultrasound validation of mathematically modeled irreversible electroporation ablation areas. Surgery. 2016; 159(4): 1032-1040.
- 41Martin EK, Bhutiani N, Egger ME, et al. Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma. HPB. 2018; 20(11): 1092-1097.
- 42Augenstein VA, Reuter NP, Bower MR, McMasters KM, Scoggins CR, Martin RCG. Bile cultures: a guide to infectious complications after pancreaticoduodenectomy. J Surg Oncol. 2010; 102(5): 478-481.
- 43Saleh MMA, Nørregaard P, Jørgensen HL, Andersen PK, Matzen P. Preoperative endoscopic stent placement before pancreaticoduodenectomy: a meta-analysis of the effect on morbidity and mortality. Gastrointest Endosc. 2002; 56(4): 529-534.
- 44Maatman TK, Weber DJ, Qureshi B, et al. Does the microbiology of bactibilia drive postoperative complications after pancreatoduodenectomy? J Gastrointest Surg. 2020; 24(11): 2544-2550.
- 45Heslin MJ. A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy. AArch Surg. 1998; 133(2): 149-154.
- 46van der Gaag NA, Rauws EAJ, van Eijck CHJ, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010; 362(2): 129-137.
- 47Povoski SP, Karpeh, Jr. MS, Conlon KC, Blumgart LH, Brennan MF. Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg. 1999; 230(2): 131-142.
- 48Cortes A, Sauvanet A, Bert F, et al. Effect of bile contamination on immediate outcomes after pancreaticoduodenectomy for tumor. J Am Coll Surg. 2006; 202(1): 93-99.
- 49Scheufele F, Aichinger L, Jäger C, et al. Effect of preoperative biliary drainage on bacterial flora in bile of patients with periampullary cancer. Br J Surg. 2017; 104(2):e182-e188.
- 50Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999; 20(11): 725-730.
